Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
47
ITRM Quote, Financials, Valuation and Earnings
Last price:
$1.76
Seasonality move
:
4.65%
Day range:
$1.75 - $1.81
52-week range:
$0.81 - $3.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
33.79x
P/B ratio:
--
Volume:
665.9K
Avg. volume:
1.4M
1-year change:
5.99%
Market cap:
$29.3M
Revenue:
--
EPS (TTM):
-$2.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics PLC
|
-- | -$0.21 | -- | -49.47% | -- |
|
ALKS
Alkermes PLC
|
$380.6M | $0.71 | 1.1% | 13.18% | $34.08 |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$1B | $5.50 | 4.77% | 311.88% | $181.05 |
|
MCKPF
Mallinckrodt PLC
|
-- | -- | -- | -- | -- |
|
MDT
Medtronic PLC
|
$8.3B | $1.25 | 2.97% | 37.4% | $96.00 |
|
PRGO
Perrigo Co PLC
|
$1.1B | $0.81 | 3.85% | 711.98% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics PLC
|
$1.77 | -- | $29.3M | -- | $0.00 | 0% | 33.79x |
|
ALKS
Alkermes PLC
|
$29.71 | $34.08 | $4.8B | 15.24x | $0.00 | 0% | 3.35x |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$123.00 | $181.05 | $7.4B | 17.32x | $0.00 | 0% | 2.04x |
|
MCKPF
Mallinckrodt PLC
|
$0.12 | -- | $2.4M | -- | $0.00 | 0% | 0.00x |
|
MDT
Medtronic PLC
|
$81.03 | $96.00 | $103.9B | 24.78x | $0.70 | 3.43% | 3.22x |
|
PRGO
Perrigo Co PLC
|
$25.75 | -- | $3.5B | -- | $0.28 | 4.29% | 0.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ITRM
Iterum Therapeutics PLC
|
-- | 1.002 | -- | -- |
|
ALKS
Alkermes PLC
|
18.27% | 1.823 | 6.38% | 2.82x |
|
JAZZ
Jazz Pharmaceuticals PLC
|
59.44% | 0.892 | 90.76% | 3.24x |
|
MCKPF
Mallinckrodt PLC
|
62.86% | 0.000 | 73639.04% | 1.43x |
|
MDT
Medtronic PLC
|
36.83% | 0.411 | 24.65% | 1.17x |
|
PRGO
Perrigo Co PLC
|
51.01% | -0.407 | 132.76% | 1.55x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics PLC
|
-- | -$6.2M | -- | -- | -- | -$13.1M |
|
ALKS
Alkermes PLC
|
$315M | $104.8M | 21.26% | 26.09% | 30.74% | $73.3M |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$943.4M | $260.2M | 4.84% | 12.28% | 24.6% | $388M |
|
MCKPF
Mallinckrodt PLC
|
$221.1M | $51.7M | -81.47% | -287.81% | 7.91% | $118.1M |
|
MDT
Medtronic PLC
|
$5.5B | $1.6B | 5.61% | 8.54% | 21.04% | $554M |
|
PRGO
Perrigo Co PLC
|
$404.4M | $113.4M | -1.8% | -3.43% | 7.3% | $15.1M |
Iterum Therapeutics PLC vs. Competitors
-
Which has Higher Returns ITRM or ALKS?
Alkermes PLC has a net margin of -- compared to Iterum Therapeutics PLC's net margin of 24.43%. Iterum Therapeutics PLC's return on equity of -- beat Alkermes PLC's return on equity of 26.09%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics PLC-- -$0.46 -- ALKSAlkermes PLC83.31% $0.55 $1.6B -
What do Analysts Say About ITRM or ALKS?
Iterum Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 323.73%. On the other hand Alkermes PLC has an analysts' consensus of $34.08 which suggests that it could grow by 14.7%. Given that Iterum Therapeutics PLC has higher upside potential than Alkermes PLC, analysts believe Iterum Therapeutics PLC is more attractive than Alkermes PLC.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics PLC0 0 0 ALKSAlkermes PLC7 4 1 -
Is ITRM or ALKS More Risky?
Iterum Therapeutics PLC has a beta of 2.404, which suggesting that the stock is 140.42% more volatile than S&P 500. In comparison Alkermes PLC has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.793%.
-
Which is a Better Dividend Stock ITRM or ALKS?
Iterum Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics PLC pays -- of its earnings as a dividend. Alkermes PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or ALKS?
Iterum Therapeutics PLC quarterly revenues are --, which are smaller than Alkermes PLC quarterly revenues of $378.1M. Iterum Therapeutics PLC's net income of -$7.1M is lower than Alkermes PLC's net income of $92.4M. Notably, Iterum Therapeutics PLC's price-to-earnings ratio is -- while Alkermes PLC's PE ratio is 15.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics PLC is 33.79x versus 3.35x for Alkermes PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M ALKSAlkermes PLC3.35x 15.24x $378.1M $92.4M
-
Which has Higher Returns ITRM or JAZZ?
Jazz Pharmaceuticals PLC has a net margin of -- compared to Iterum Therapeutics PLC's net margin of 20.39%. Iterum Therapeutics PLC's return on equity of -- beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics PLC-- -$0.46 -- JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B -
What do Analysts Say About ITRM or JAZZ?
Iterum Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 323.73%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 47.2%. Given that Iterum Therapeutics PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Iterum Therapeutics PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics PLC0 0 0 JAZZJazz Pharmaceuticals PLC8 3 0 -
Is ITRM or JAZZ More Risky?
Iterum Therapeutics PLC has a beta of 2.404, which suggesting that the stock is 140.42% more volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.
-
Which is a Better Dividend Stock ITRM or JAZZ?
Iterum Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or JAZZ?
Iterum Therapeutics PLC quarterly revenues are --, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Iterum Therapeutics PLC's net income of -$7.1M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, Iterum Therapeutics PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 17.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics PLC is 33.79x versus 2.04x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M JAZZJazz Pharmaceuticals PLC2.04x 17.32x $1.1B $215.1M
-
Which has Higher Returns ITRM or MCKPF?
Mallinckrodt PLC has a net margin of -- compared to Iterum Therapeutics PLC's net margin of -5.18%. Iterum Therapeutics PLC's return on equity of -- beat Mallinckrodt PLC's return on equity of -287.81%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics PLC-- -$0.46 -- MCKPFMallinckrodt PLC43.74% -$1.33 $2.8B -
What do Analysts Say About ITRM or MCKPF?
Iterum Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 323.73%. On the other hand Mallinckrodt PLC has an analysts' consensus of -- which suggests that it could fall by --. Given that Iterum Therapeutics PLC has higher upside potential than Mallinckrodt PLC, analysts believe Iterum Therapeutics PLC is more attractive than Mallinckrodt PLC.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics PLC0 0 0 MCKPFMallinckrodt PLC0 0 0 -
Is ITRM or MCKPF More Risky?
Iterum Therapeutics PLC has a beta of 2.404, which suggesting that the stock is 140.42% more volatile than S&P 500. In comparison Mallinckrodt PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ITRM or MCKPF?
Iterum Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mallinckrodt PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics PLC pays -- of its earnings as a dividend. Mallinckrodt PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or MCKPF?
Iterum Therapeutics PLC quarterly revenues are --, which are smaller than Mallinckrodt PLC quarterly revenues of $505.5M. Iterum Therapeutics PLC's net income of -$7.1M is higher than Mallinckrodt PLC's net income of -$26.2M. Notably, Iterum Therapeutics PLC's price-to-earnings ratio is -- while Mallinckrodt PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics PLC is 33.79x versus 0.00x for Mallinckrodt PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M MCKPFMallinckrodt PLC0.00x -- $505.5M -$26.2M
-
Which has Higher Returns ITRM or MDT?
Medtronic PLC has a net margin of -- compared to Iterum Therapeutics PLC's net margin of 15.11%. Iterum Therapeutics PLC's return on equity of -- beat Medtronic PLC's return on equity of 8.54%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics PLC-- -$0.46 -- MDTMedtronic PLC64.94% $0.99 $77B -
What do Analysts Say About ITRM or MDT?
Iterum Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 323.73%. On the other hand Medtronic PLC has an analysts' consensus of $96.00 which suggests that it could grow by 18.48%. Given that Iterum Therapeutics PLC has higher upside potential than Medtronic PLC, analysts believe Iterum Therapeutics PLC is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics PLC0 0 0 MDTMedtronic PLC11 14 1 -
Is ITRM or MDT More Risky?
Iterum Therapeutics PLC has a beta of 2.404, which suggesting that the stock is 140.42% more volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.999%.
-
Which is a Better Dividend Stock ITRM or MDT?
Iterum Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.43% to investors and pays a quarterly dividend of $0.70 per share. Iterum Therapeutics PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ITRM or MDT?
Iterum Therapeutics PLC quarterly revenues are --, which are smaller than Medtronic PLC quarterly revenues of $8.4B. Iterum Therapeutics PLC's net income of -$7.1M is lower than Medtronic PLC's net income of $1.3B. Notably, Iterum Therapeutics PLC's price-to-earnings ratio is -- while Medtronic PLC's PE ratio is 24.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics PLC is 33.79x versus 3.22x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M MDTMedtronic PLC3.22x 24.78x $8.4B $1.3B
-
Which has Higher Returns ITRM or PRGO?
Perrigo Co PLC has a net margin of -- compared to Iterum Therapeutics PLC's net margin of -1.93%. Iterum Therapeutics PLC's return on equity of -- beat Perrigo Co PLC's return on equity of -3.43%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics PLC-- -$0.46 -- PRGOPerrigo Co PLC37.19% -$0.15 $9.3B -
What do Analysts Say About ITRM or PRGO?
Iterum Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 323.73%. On the other hand Perrigo Co PLC has an analysts' consensus of -- which suggests that it could grow by 39.03%. Given that Iterum Therapeutics PLC has higher upside potential than Perrigo Co PLC, analysts believe Iterum Therapeutics PLC is more attractive than Perrigo Co PLC.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics PLC0 0 0 PRGOPerrigo Co PLC0 0 0 -
Is ITRM or PRGO More Risky?
Iterum Therapeutics PLC has a beta of 2.404, which suggesting that the stock is 140.42% more volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.517, suggesting its less volatile than the S&P 500 by 48.32%.
-
Which is a Better Dividend Stock ITRM or PRGO?
Iterum Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.29% to investors and pays a quarterly dividend of $0.28 per share. Iterum Therapeutics PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -1178.74% of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or PRGO?
Iterum Therapeutics PLC quarterly revenues are --, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Iterum Therapeutics PLC's net income of -$7.1M is higher than Perrigo Co PLC's net income of -$21M. Notably, Iterum Therapeutics PLC's price-to-earnings ratio is -- while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics PLC is 33.79x versus 0.80x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics PLC33.79x -- -- -$7.1M PRGOPerrigo Co PLC0.80x -- $1.1B -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
